First Week of February 2026 Options Trading For Guardant Health (GH)

Guardant Health (GH) is highlighted for two option strategies around the current stock price of $98.25: a sell-to-open $85 put (bid $4.10) which nets a $80.90 effective cost basis and is ~13% OTM with a 74% probability of expiring worthless, yielding 4.82% (27.95% annualized) if it does; and a covered call at the $100 strike (bid $8.10) that would produce a 10.03% total return to Feb 2026 and an 8.24% premium boost (47.76% annualized) if the call expires worthless (47% probability). Implied volatilities are 69% (put) and 64% (call) versus a trailing 12‑month volatility of 63%, with the article framed as option trade ideas rather than new company fundamental news.

Analysis

Market structure: Option sellers and income-seeking investors benefit from elevated long-dated premia (put IV 69%, call IV 64% vs realized 63%), while pure upside-biased holders are hurt by capped-return covered-call strategies. The $85 put (premium $4.10 → effective cost basis $80.90) signals demand for downside protection and sellers willing to own stock at ~18% below spot; liquidity and wide bid/ask in Feb‑2026 strikes are likely and raise execution risk. Cross-asset impact is marginal today but a negative GH clinical/regulatory shock would widen high‑yield and small‑cap credit spreads and lift implied vol across biotech (IBB), with minimal FX or commodity linkage.

Risk assessment: Tail risks include a failed pivotal study or surprise need to raise capital—each could drive a 30–60% drop in GH within 30–90 days and materially increase IV beyond 100%. Immediate (days) risk is IV/quote moves and assignment around news; short term (1–6 months) hinge on earnings/regulatory catalysts; long term (12–36 months) depends on product adoption and payer reimbursement. Hidden dependencies: potential equity secondary issuance, heavy revenue concentration by product, and broker illiquidity in long-dated options.

Trade implications: For income-biased exposure, cash‑secured $85 Feb‑2026 puts (collected $4.10) or buying stock + selling $100 calls (collect $8.10) are logical—size them 1–3% of portfolio and treat assignment as deliberate buy at $80.90. If downside protection is required, prefer a put‑credit spread (sell $85 / buy $70) to cap tail losses or buy closer protective puts (e.g., $75) around major catalysts. Avoid unhedged long volatility plays; IV premium vs realized is small, so long straddles are expensive unless expecting a binary clinical event.

Contrarian angles: The market may be underpricing the left tail—long‑dated OTM put sellers are implicitly short low‑probability regulatory shocks and dilution risk; historical parallels include post‑secondary biotech drawdowns where assignment left buyers holding impaired shares. Conversely, if no negative catalysts arrive, current sellers can realize 4–8% gross yields (27–48% annualized) but watch for IV spikes and thin order books that can flip P/L quickly.

Key Decisions for Investors

• Establish a cash‑secured put: Sell GH Feb‑2026 $85 put (collect ~$4.10) size 2% of portfolio; plan to accept assignment and own GH at $80.90. Close the short if GH trades below $70 or if IV rises >30 pts (e.g., to >95%).
• Covered‑call alternative: Buy 100 GH and sell Feb‑2026 $100 call (collect ~$8.10) for an expected 10% capped return to Feb‑2026; size 1–2% portfolio. Exit/roll if GH >$110 or if a positive catalyst (FDA/earnings) is announced with >15% gap up.
• Put‑credit spread for defined risk: Sell GH Feb‑2026 $85 / Buy Feb‑2026 $70 put to limit downside; target net credit >$2.00 (adjust size to cap max loss at ~12–15% of position). Close spreads 30–45 days before major catalysts or if GH < $75.
• Relative trade: Pair long GH (via put sell or outright buy) vs short Exact Sciences (EXAS) equal notional 1:1 to hedge sector beta; initial net exposure 1% of portfolio and reassess after next quarterly reports. Trigger unwind if the pair diverges >20% over 90 days.
• Monitor and act on catalysts: Do not add net long exposure larger than planned until 90 days pass without dilution notices; specifically, exit or hedge if company files a shelf or announces secondary, or if IV rises to >90% ahead of an FDA/clinical readout.